» Articles » PMID: 11751962

Elevated NF-kappaB Activation in Nonobese Diabetic Mouse Dendritic Cells Results in Enhanced APC Function

Overview
Journal J Immunol
Date 2001 Dec 26
PMID 11751962
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently demonstrated that dendritic cells (DC) prepared from nonobese diabetic (NOD) mice, a spontaneous model for insulin-dependent diabetes mellitus, exhibit elevated levels of NF-kappaB activation upon stimulation. In the current study, we investigated the influence of dysregulation of NF-kappaB activation on the APC function of bone marrow-derived DC prepared from NOD vs BALB/c and nonobese diabetes-resistant mice. NOD DC pulsed with either peptide or virus were found to be more efficient than BALB/c DC at stimulating in vitro naive Ag-specific CD8+ T cells. The T cell stimulatory capacity of NOD DC was suppressed by gene transfer of a modified form of IkappaBalpha, indicating a direct role for NF-kappaB in this process. Furthermore, neutralization of IL-12(p70) to block autocrine-mediated activation of DC also significantly reduced the capacity of NOD DC to stimulate T cells. Despite a reduction in low molecular mass polypeptide-2 expression relative to BALB/c DC, no effect on proteasome-dependent events associated with the NF-kappaB signaling pathway or Ag processing was detected in NOD DC. Finally, DC from nonobese diabetes-resistant mice, a strain genotypically similar to NOD yet disease resistant, resembled BALB/c and not NOD DC in terms of the level of NF-kappaB activation, secretion of IL-12(p70) and TNF-alpha, and the capacity to stimulate T cells. Therefore, elevated NF-kappaB activation and enhanced APC function are specific for the NOD genotype and correlate with the progression of insulin-dependent diabetes mellitus. These results also provide further evidence indicating a key role for NF-kappaB in regulating the APC function of DC.

Citing Articles

Sinomenine in Cardio-Cerebrovascular Diseases: Potential Therapeutic Effects and Pharmacological Evidences.

Zhang M, Wang X, Shi J, Yu J Front Cardiovasc Med. 2021; 8:749113.

PMID: 34660748 PMC: 8517137. DOI: 10.3389/fcvm.2021.749113.


Innate immunity in latent autoimmune diabetes in adults.

Huang J, Pearson J, Wong F, Wen L, Zhou Z Diabetes Metab Res Rev. 2021; 38(1):e3480.

PMID: 34156143 PMC: 8813511. DOI: 10.1002/dmrr.3480.


miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes.

Scherm M, Daniel C Front Endocrinol (Lausanne). 2020; 11:606322.

PMID: 33329406 PMC: 7731293. DOI: 10.3389/fendo.2020.606322.


Regulatory T Cells Induced by Single-Peptide Liposome Immunotherapy Suppress Islet-Specific T Cell Responses to Multiple Antigens and Protect from Autoimmune Diabetes.

Bergot A, Buckle I, Cikaluru S, Naranjo J, Wright C, Zheng G J Immunol. 2020; 204(7):1787-1797.

PMID: 32111734 PMC: 9352518. DOI: 10.4049/jimmunol.1901128.


Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?.

Funda D, Palova-Jelinkova L, Golias J, Kroulikova Z, Fajstova A, Hudcovic T Front Immunol. 2019; 10:967.

PMID: 31139178 PMC: 6527741. DOI: 10.3389/fimmu.2019.00967.